The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) hit a new 52-week high and has $35.78 target or 8.00% above today’s $33.13 share price. The 9 months bullish chart indicates low risk for the $610.12 million company. The 1-year high was reported on Nov, 22 by Barchart.com. If the $35.78 price target is reached, the company will be worth $48.81M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 131,898 shares traded hands. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has declined 3.59% since April 20, 2016 and is downtrending. It has underperformed by 8.15% the S&P500.
Analysts await Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report earnings on November, 28. They expect $-0.28 earnings per share, down 196.55% or $0.57 from last year’s $0.29 per share. After $-0.06 actual earnings per share reported by Enanta Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 366.67% negative EPS growth.
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage
Out of 4 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 25% are positive. $45 is the highest target while $16 is the lowest. The $24.50 average target is -26.05% below today’s ($33.13) stock price. Enanta Pharmaceuticals Inc has been the topic of 11 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Underweight” rating given by Barclays Capital on Friday, October 23. On Friday, August 7 the stock rating was downgraded by Zacks to “Buy”. The firm earned “Market Perform” rating on Thursday, April 28 by JMP Securities. On Tuesday, August 9 the stock rating was maintained by JP Morgan with “Overweight”. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Buy” rating given on Saturday, August 8 by TheStreet. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) earned “Mkt Outperform” rating by JMP Securities on Friday, October 23.
According to Zacks Investment Research, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.53 in 2016 Q2. Its up 0.83, from 0.7 in 2016Q1. The ratio is positive, as 29 funds sold all Enanta Pharmaceuticals Inc shares owned while 42 reduced positions. 9 funds bought stakes while 41 increased positions. They now own 13.13 million shares or 4.44% less from 13.75 million shares in 2016Q1.
Brown Brothers Harriman has 0% invested in the company for 93 shares. Fiera has invested 0.07% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Matarin Limited holds 0% or 236,690 shares in its portfolio. State Of Tennessee Treasury Department has 10,446 shares for 0% of their US portfolio. Northern Trust last reported 0% of its portfolio in the stock. Secor Capital Lp accumulated 42,938 shares or 0.12% of the stock. Schwab Charles Inv last reported 0% of its portfolio in the stock. Principal Financial Inc has 0% invested in the company for 93,477 shares. New York State Teachers Retirement System last reported 41,790 shares in the company. Krensavage Asset Mgmt Ltd Com last reported 906,930 shares in the company. Blackrock Japan has invested 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Schroder Gru holds 0% or 29,652 shares in its portfolio. Deutsche Bancorp Ag holds 0% or 125,579 shares in its portfolio. Credit Suisse Ag holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 27,565 shares. Teacher Retirement Systems Of Texas last reported 1,990 shares in the company.
More recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Businesswire.com which released: “Enanta Pharmaceuticals Announces the Appointment of Dr. Lesley Russell to Its …” on November 22, 2016. Also Marketwatch.com published the news titled: “/quotes/zigman/3870025/realtime” on March 25, 2013. Quotes.Wsj.com‘s news article titled: “News Enanta Pharmaceuticals Inc.ENTA” with publication date: March 22, 2013 was also an interesting one.
ENTA Company Profile
Enanta Pharmaceuticals Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Firm uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Firm is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.